Note 2 - Current Developments and Liquidity	6 Months Ended
Jun. 30, 2026
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	(2) Current Developments and Liquidity Business Condition – Since inception, the Company has incurred substantial losses. During the six months ended June 30, 2026, the Company reported a net loss of $2,230,083 and net cash used in operating activities of $686,000. During the six months ended June 30, 2025, the Company reported net loss of $273,479 and net cash provided by operating activities of $310,446. During the three and six months ended June 30, 2026, the Company (a) continued its focus on its four core business segments which consist of its Theranostics Products (previously called Radiochemical Products), Calibration & Reference Products (previously called Nuclear Medicine Standards), Cobalt Products, and the start-up of its Medical Device segment, which includes assets purchased from AMICI, Inc. (AMICI) in 2023, investing in the development of an EasyFill Iodine Encapsulation System, and development of the radiation sensing assets purchased from Lucerno Dynamics, LLC (Lucerno) on June 25, 2026. The Company holds a Nuclear Regulatory Commission (NRC) construction and operating license for the depleted uranium facility in, as well as the property agreement with, Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a forty (40) year operating license and is the first commercial license of this type issued in the United States. On March 11, 2026, the Company executed a mutual termination of an asset purchase agreement ("DUF6 Asset Sale") dated February 8, 2024 to sell all our assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility to American Fuel Resources ("AFR"). AFR contacted the Company requesting a 1-year extension due to AFR being unable to make payment of the balance of the purchase price by March 31, 2026 (the “Outside Date”) in order to meet the Condition to Seller’s Obligations as defined in the DUF6 Asset Sale. The parties were in the final stages of the NRC consent process and were on the cusp of receiving NRC consent to transfer; however, the parties mutually agreed to withdraw the application and terminate the APA. Proceeds from this sale would have been $12.5 million in total. The Company decided it was in the best interest of the shareholders to regain control of the assets as we believe they have appreciated in value since we had entered the DUF6 Asset Sale and it had low confidence that AFR would have been able to secure funding to close the deal by the requested extension date. The Company is actively working towards monetizing the NRC license. The Company expects that cash from operations, the availability of equity or debt financing, possible asset sales, and its current cash balance will be sufficient to fund operations for the next twelve months. Future liquidity and capital funding requirements will depend on numerous factors, including commercial relationships, technological developments, market factors, available credit, and management of redeemable convertible preferred stock. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

Note 2 - Current Developments and Liquidity

6 Months Ended

Jun. 30, 2026

Substantial Doubt about Going Concern [Text Block]

(2) Current Developments and Liquidity

Business Condition – Since inception, the Company has incurred substantial losses. During the six months ended June 30, 2026, the Company reported a net loss of $2,230,083 and net cash used in operating activities of $686,000. During the six months ended June 30, 2025, the Company reported net loss of $273,479 and net cash provided by operating activities of $310,446.

During the three and six months ended June 30, 2026, the Company (a) continued its focus on its four core business segments which consist of its Theranostics Products (previously called Radiochemical Products), Calibration & Reference Products (previously called Nuclear Medicine Standards), Cobalt Products, and the start-up of its Medical Device segment, which includes assets purchased from AMICI, Inc. (AMICI) in 2023, investing in the development of an EasyFill Iodine Encapsulation System, and development of the radiation sensing assets purchased from Lucerno Dynamics, LLC (Lucerno) on June 25, 2026.

The Company holds a Nuclear Regulatory Commission (NRC) construction and operating license for the depleted uranium facility in, as well as the property agreement with, Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a forty (40) year operating license and is the first commercial license of this type issued in the United States. On March 11, 2026, the Company executed a mutual termination of an asset purchase agreement ("DUF6 Asset Sale") dated February 8, 2024 to sell all our assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility to American Fuel Resources ("AFR"). AFR contacted the Company requesting a 1-year extension due to AFR being unable to make payment of the balance of the purchase price by March 31, 2026 (the “Outside Date”) in order to meet the Condition to Seller’s Obligations as defined in the DUF6 Asset Sale. The parties were in the final stages of the NRC consent process and were on the cusp of receiving NRC consent to transfer; however, the parties mutually agreed to withdraw the application and terminate the APA. Proceeds from this sale would have been $12.5 million in total. The Company decided it was in the best interest of the shareholders to regain control of the assets as we believe they have appreciated in value since we had entered the DUF6 Asset Sale and it had low confidence that AFR would have been able to secure funding to close the deal by the requested extension date. The Company is actively working towards monetizing the NRC license.

The Company expects that cash from operations, the availability of equity or debt financing, possible asset sales, and its current cash balance will be sufficient to fund operations for the next twelve months. Future liquidity and capital funding requirements will depend on numerous factors, including commercial relationships, technological developments, market factors, available credit, and management of redeemable convertible preferred stock. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

- Definition

The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.

+ References + Details